Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

99mTc-1-thio-D-glucose

Preclinical

TTomsk National Research Medical Center of the Russian Academy of Sciences

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glioma (any Grade) in the BrainActive, not recruiting

Glioma (any Grade) in the BrainPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

PreclinicalActive, not recruiting

Glioma (any Grade) in the Brain

NCT07475390

Clinical

Trials by Indication[1]

Glioma (Any Grade) in the Brain1 trial

Molecular Imaging of Brain Tumor Using 99mTc-1-thio-D-glucose SPECT/CT and 18F-Fluoroethyl-l-tyrosine PET/CT in Primary and Recurrent Glioma Patients

Active, not recruiting·TTomsk National Research Medical Center of the Russian Academy of Sciences·Preclinical·NCT07475390·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 99mTc-1-thio-D-glucose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 99mTc-1-thio-D-glucose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tomsk National Research Medical Center of the Russian Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TTomsk National Research Medical Center of the Russian Academy of Sciences

Related News